The CorEvitas Psoriasis (PSO) Registry

Part of paid clinical trials in Waltham, Massachusetts.

Sponsor
CorEvitas
Study ID
NCT02707341
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The primary objective of the CorEvitas Psoriasis Registry is to study the comparative safety of approved psoriasis therapies in a North American cohort of psoriasis subjects treated by dermatologists. This includes assessing the incidence and nature of adverse events of special interest, including malignancy, in a real world population of psoriasis patients on new biologic therapies (e.g. secukinumab). Secondary objectives include analyzing the epidemiology and natural history of the disease, comorbidities, current treatment practices, and comparative effectiveness.

Key Dates

First listed
Mar 14, 2016
Start date
Apr 30, 2015
Status verified
Aug 2026
Primary completion
Dec 31, 2100
Completion
Dec 31, 2100

Study Design

Enrollment
10,000 participants (estimated)

Arms

  • Arm: Psoriasis
    Pts presenting to enrolling sites across the US are invited to enroll if eligible

Primary Outcome Measure

Number of patients with adverse events (AEs) or serious adverse events (SAEs). [ Time Frame: A minimum of 8 years from last patient enrolled ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
-WalthamMassachusetts02451-

Find similar trials in Waltham, MA

Nationwide
Psoriasis trialsDermatology trialsRheumatology trialsAutoimmune disease trials
By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease

Related Studies